Grisovin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Grisovin

Quick Facts about Grisovin (Griseofulvin)

Property Description
Active ingredient Griseofulvin (INN)
Form Oral dosage forms (Tablet, Capsule, Suspension)
Pharmacological class Antifungal agent (Antimycotic)
Common use Systemic treatment of fungal infections (Dermatophytosis)
Origin Natural product derivative (from Penicillium griseofulvum)

What Type of Medicine is Grisovin (Griseofulvin)?

Grisovin is a specific brand name for the systemic, prescription-only medication whose active ingredient is Griseofulvin (INN). The medication is classified as a miscellaneous antifungal agent. This classification establishes that the medicine is primarily recognized as a fungistatic agent because it inhibits fungal growth rather than directly destroying the cells. Its long history of use is supported by pharmacological studies that consistently confirm its efficacy against dermatophyte fungi, making it clinically recognized for treating persistent fungal infections of the hair, skin, and nails.

Griseofulvin Composition and Its Unique Differentiation

The core component, Griseofulvin, is a natural product derivative, specifically a polyketide metabolite produced by the mold Penicillium griseofulvum. A key differentiating feature is its pharmaceutical formulation for oral consumption: it is available in standard tablets and capsules, as well as an oral suspension, which is often preferred for pediatric patients. Due to its low solubility, the medication requires specialized particle sizing—notably microsize and ultramicrosize formulations—to ensure proper absorption from the gastrointestinal tract.

General Purpose of Systemic Antifungal Therapy

The general purpose of this therapy is to suppress the growth and spread of susceptible fungal infections throughout the body's tissues via its fungistatic effect. Once absorbed, Griseofulvin works systemically by interfering with the fungal cell division, or mitosis, thereby halting the organism's reproduction. This requirement for systemic therapy is vital because it allows the drug to be deposited into newly forming tissues of the skin, hair, and nails, creating an internal fungistatic barrier that protects new tissue as the infected material is gradually replaced.

Regulatory References

  1. FDA Drug Label
  2. World Health Organization's essential medicines list
  3. WHO Essential Medicines

What side effects are possible with Grisovin?

Possible Side Effects and Safety Information

The safety profile of Griseofulvin, the active ingredient in Grisovin, is officially classified by regulatory authorities based on the affected System-Organ Classes and the frequency of adverse reactions. Most frequently reported side effects involve the Gastrointestinal System and Nervous System.

Frequency-Classified Adverse Reactions

Frequency Classification Examples of Officially Documented Effects
Common Headache (may be severe initially), nausea, vomiting, diarrhea, abdominal discomfort.
Uncommon / Occasional Insomnia, mental confusion, dizziness, skin rash, elevated liver enzymes.

Serious Adverse Reactions and Safety Constraints

Although rare, officially documented serious adverse reactions include severe hepatotoxicity (liver damage or failure), severe cutaneous reactions (such as Stevens-Johnson Syndrome), and blood dyscrasias (like leukopenia). These serious events are generally associated with high doses or prolonged exposure.

Regulatory documents outline specific safety constraints.

  • Contraindications: The medicine is contraindicated in pregnancy due to the risk of fetal harm. It is also restricted in individuals with porphyria or severe hepatic failure.
  • Photosensitivity: The labeling notes the risk of photosensitivity reactions; patients should avoid intense sunlight exposure.
  • Monitoring: Periodic monitoring of renal, hepatic, and blood function is required during extended therapy. Furthermore, Griseofulvin may officially reduce the effectiveness of oral contraceptives.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory information indicates that acute overdosage with Grisovin (griseofulvin) is generally stated to be unlikely to require specific treatment beyond supportive measures. However, any suspected overdose requires immediate medical attention. You must contact a doctor or the nearest hospital at once, providing details on the amount ingested and any concurrent medications.

The primary regulatory concern for high exposure or prolonged therapy is the risk of serious and potentially life-threatening outcomes. These severe manifestations are linked in the official labeling to high dosages and long periods of use. They affect the Hepatic (liver), Cutaneous (skin), and Hematopoietic (blood) systems. Documented severe outcomes include hepatotoxicity, which can present as jaundice and elevated liver enzymes, and severe skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These conditions may necessitate hospitalization.

Manifestations associated with high exposure also include CNS effects like mental confusion, dizziness, fatigue, and paresthesia. Since no specific antidote is known, management is symptomatic and supportive. Regulatory documents require periodic monitoring of hepatic, renal, and hematopoietic functions, especially when serious adverse reactions or high exposure have occurred.

Therapeutic Uses of Grisovin

Grisovin, which contains the active ingredient griseofulvin, is an oral antifungal medication primarily used in situations involving certain distressing symptoms that affect the skin, hair, and nails. Its core therapeutic domain is commonly used to help with managing ringworm infections, technically known as dermatophytoses.

Major indications include tinea corporis (ringworm of the body), tinea capitis (ringworm of the scalp), tinea pedis (athlete's foot), and tinea unguium (nail ringworm).

The medicine is applied in scenarios where additional management of discomfort is required, particularly when the fungal infection is widespread, chronic, or has not responded to topical (cream/lotion) treatments. This contributes to improved comfort during periods of heightened symptoms.

“Treatment may assist with addressing the overall symptom burden, which helps improve day-to-day comfort.”

Treatment supports general well-being during symptomatic phases associated with symptoms that interfere with daily functioning.

Quick Fact: Relief for Skin and Nail Symptoms

Eligibility and Restrictions for Use

Grisovin (Griseofulvin) use is defined by strict population eligibility rules outlined in official regulatory labeling. The medicine is primarily approved for adults and children for the systemic treatment of dermatophytoses, but its use is restricted by several absolute contraindications.


Absolute Contraindications (Must Not Use)

Official documents state that Grisovin is contraindicated in patients with:

  • A history of Porphyria or Severe Hepatic Impairment (Hepatocellular Failure).
  • Systemic Lupus Erythematosus (SLE), as noted in certain international labels.
  • Documented Hypersensitivity to griseofulvin.

Eligibility Status by Physiological Condition

Condition Regulatory Status
Pregnancy CONTRAINDICATED (FDA Category X for microsize formulation).
Lactation Use should be avoided; safety not established in nursing infants.
Childbearing Potential Requires mandatory contraception for females (4 weeks post-treatment) and males (6 months post-treatment).
Mild Hepatic Impairment Requires regular monitoring of liver function during use.

Eligibility is generally reserved for established, widespread infections and is not justified for minor conditions treatable with topical agents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Grisovin (griseofulvin) is officially documented by regulatory authorities, largely stemming from its classification as a hepatic enzyme inducer. This effect accelerates the metabolism of certain co-administered medicines, reducing their plasma concentrations and potentially diminishing their therapeutic effect.

Documented Pharmacokinetic Interactions

Interacting Substance Official Interaction Outcome Constraint Type
Warfarin-type Anticoagulants Decreases the activity of the anticoagulant. Monitoring/Adjustment
Oral Contraceptives (Estrogen) Reduces efficacy, increasing breakthrough bleeding risk. Alternative Contraception Mandated
Ciclosporin, Methadone Reduces plasma levels of the co-administered drug. Monitoring/Adjustment
Barbiturates (e.g., Phenobarbitone) Decreases griseofulvin plasma levels. Monitoring/Adjustment

Pharmacodynamic and Administration Restrictions

Griseofulvin carries a formal restriction against concurrent use with alcohol (ethanol). This co-administration enhances the central nervous system effects of alcohol and has been reported to cause a severe Disulfiram-like reaction (e.g., flushing, tachycardia, hypotension).

Separation of administration is required for drugs that impede absorption. Antacids and H2 antagonists should be spaced from Grisovin by approximately two hours, as they may impair its necessary gastrointestinal absorption. Conversely, the official labeling notes that absorption is enhanced when microsize griseofulvin is taken with a fatty meal.

Furthermore, regulatory documents impose strict contraception timing rules. Women must use effective alternative contraception for four weeks after stopping therapy, while men must use effective barrier contraception for six months post-therapy, due to interaction-related reproductive risk.

Mechanism of Action

Grisovin (griseofulvin) exerts a fungistatic action through a two-part pharmacodynamic mechanism that targets the fungal cell's structure and the host's tissue growth.

Targeting Fungal Mitosis and the Microtubule System

The molecule acts as a microtubule assembly inhibitor by binding specifically to tubulin subunits within the fungal cell. This molecular interaction disrupts the formation of the mitotic spindle apparatus, causing a physical arrest of the fungal cell cycle at metaphase. This initial step results in suppressing fungal proliferation and blocks the cellular process of dissemination.

Systemic Protection via Keratin Tissue Saturation

Following systemic distribution, the molecule demonstrates a high affinity for keratin precursor cells in the host. As these cells mature into new tissue, the drug is incorporated, creating layers of drug-saturated keratin that are chemically resistant to fungal invasion. This physiological effect involves the gradual replacement of existing tissue with drug-saturated tissue, a process determined solely by the inherent rate of keratinized tissue growth. This dual mechanism ensures that the pathogen's ability to propagate is blocked while the newly forming host tissue is structurally protected.

Dosage and Administration Information

How to Use Grisovin: Official Administration Guidelines

The administration of Grisovin (griseofulvin) is strictly via the oral route, available in microsize and ultramicrosize formulations. Official dosing regimens are determined by the specific formulation and the site of the infection.

Standard Regimens and Frequency

For adults, the total daily dose typically ranges from 375 mg to 1000 mg, depending on the formulation and the difficulty of eradicating the infection, such as those affecting the feet or nails. The medication may be administered as a single daily dose or in divided doses to maintain steady systemic levels, a pattern sometimes recommended for patients who respond poorly to initial therapy.

Administration Timing and Duration

A critical instruction is that the medication must be consumed with or immediately after a high-fat meal (such as milk or fatty foods). This practice is officially mandated because griseofulvin's poor absorption from the gastrointestinal tract is significantly enhanced by fat, increasing its bioavailability.

The duration of use is non-fixed and is uniquely tied to the biological process of tissue replacement. Treatment must continue without interruption until the infected keratin of the skin, hair, or nails is completely replaced by new, non-infected tissue. This necessitates courses ranging from two to four weeks for certain skin infections to six to twelve months for fungal nail infections. For pediatric patients, dosing is weight-based, often targeting 10 mg/kg per day.

Recent Clinical Evidence

Research evidence / Overview of Studies for Grisovin

Evidence for Use in Tinea Capitis (Scalp Ringworm)

The research into Griseofulvin for scalp ringworm, known as tinea capitis, has utilized a substantial base of Randomized Controlled Trials (RCTs). These are studies that provide a basis for comparing different treatments. The evidence also includes several Meta-analyses, where data from many different RCTs are collected and examined together.

Research has primarily explored the use of Griseofulvin in pediatric patients (children), as this group is frequently studied for tinea capitis. The studies monitored key outcomes related to how the fungal infection evolved. Researchers measured mycological status (clearance verified by lab tests) and clinical status (the visual appearance of scalp lesions). Studies monitored that the observation of outcomes required a sustained duration over multiple weeks.

The consistency of findings across all specific fungal types remains an area of uncertainty. Some research has noted patterns where mycological endpoints appear to vary based on the specific species of fungus causing the infection, such as Microsporum or Trichophyton.

Evidence for Use in Tinea Unguium (Nail Ringworm)

For nail ringworm, or tinea unguium, evidence includes Controlled Open Trials and Comparative Randomized Trials. These studies were applied in research exploring how symptoms change over time in adult patients with mycologically confirmed nail infections. The long-term nature of nail growth means that the research necessarily involved extended observation periods.

Studies monitored outcomes related to the status of the infection over defined time intervals. Primary outcomes included the assessment of mycological endpoints and the clinical status as new, uninfected nail growth progressed. Findings describe patterns observed in the studies that were highly dependent on the slow biological process of nail growth, meaning study periods often extended from several months up to a year or longer.

Due to the necessity for these very long treatment periods, evidence for a broad patient base is limited, and interpretation is complex when compared to short-term studies.

Research Gaps and Areas of Uncertainty

Research highlights the variability in findings noted across different trials, particularly regarding outcomes being tied to the specific fungal species causing the infection.

Another uncertainty is that comparative evidence is lacking in some areas, such as the direct assessment of outcomes between the different microsize and ultramicrosize formulations. The evidence landscape varies across studies. Some aspects of Griseofulvin's long-term use and outcomes in specific patient subgroups remain areas for continued study.

Key Studies & References

  1. Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis
  2. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis
  3. GRISEOFULVIN TABLETS, USP (MICROSIZE) 500 MG Rx ONLY (FDA Label/DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Grisovin (FAQ)


Q: Is Grisovin a safe medication to take long-term, given the long treatment periods for some infections?

Because Grisovin may be taken for extended periods, official product information notes that close observation is required. Periodic monitoring of renal, hepatic, and blood function is recommended in regulatory documents during extended therapy. Furthermore, the clinical importance of certain long-term effects observed in high-dose animal studies is not known for humans.


Q: Can Grisovin cause dizziness or drowsiness, and what activities should be avoided?

Regulatory documents list central nervous system effects such as headache, dizziness, and mental confusion as possible side effects. The active ingredient griseofulvin is generally not reported as causing drowsiness in regulatory documents, although other central nervous system effects like dizziness and confusion have been noted. Due to reported effects like dizziness and confusion, regulatory documents advise that patients should be aware of these possibilities when engaging in activities requiring mental alertness.


Q: What is porphyria, and why is Grisovin not recommended for people with this condition?

Porphyria is a rare metabolic disorder. Grisovin is officially contraindicated (should not be used) in patients with a history of this condition. The restriction exists because the drug has been reported in laboratory studies to interfere with porphyrin metabolism, which is a concern for this condition.


Q: What happens if the full prescribed course of Grisovin is not completed?

Official guidance emphasizes that treatment must continue for the full duration without interruption until the infected tissue is completely replaced by healthy, new tissue. Stopping the medicine too soon, even if symptoms appear to have cleared, is known to increase the risk that the fungal infection will not be fully eliminated, potentially leading to recurrence.


Q: Do medical studies show high cure rates for fungal infections treated with Grisovin?

Studies have reported findings related to both clinical signs and mycological clearance (lab evidence of fungal absence), but the results show variability. Research has noted that response rates can vary depending on the specific species of fungus causing the infection. Due to this variability, extended treatment periods are often observed in clinical practice to achieve a sustained outcome.


Q: How long after starting Grisovin can a person expect to see the first signs of improvement?

The medication's fungistatic action begins when it is absorbed. However, visible signs of improvement depend entirely on the natural rate at which new, healthy tissue replaces the infected tissue. Noticeable changes in skin, hair, or nails usually appear gradually over several days or weeks, rather than instantly.


Q: Can Grisovin still be effective if I sometimes miss a dose?

Official drug labels contain specific instructions on how to proceed if a dose is missed. It is important to avoid large gaps between doses to maintain consistent drug levels in the body, as this consistency supports the long-term effectiveness of the therapy.


Q: Does Grisovin interact with other common medications like aspirin or supplements?

Official drug interaction information indicates that Grisovin may reduce the effectiveness of medications in the salicylate class (which includes aspirin). The official labeling strongly recommends that patients inform their prescriber of all co-administered products and supplements.


Q: Is there a benefit to taking Grisovin at night versus during the day?

The medication is required to be taken with or right after a high-fat meal to ensure it is properly absorbed into the body. Taking the drug at night is a common approach used to ensure consistent timing with a fatty meal, as reliable drug absorption is dependent on consumption with food.


Q: Can Grisovin be split or crushed, or must it be swallowed whole?

Official administration instructions indicate that the tablets can be swallowed whole. In certain formulations, the tablet may be cut or crushed and then mixed with a tablespoon of soft food, such as applesauce, and swallowed immediately. The specific formulation's instruction determines whether manipulation is permitted.


Q: Is Grisovin still commonly used, or has it been replaced by newer antifungal drugs in most cases?

While newer antifungal drugs have become available, Grisovin continues to be a standard treatment option, supported by decades of established clinical experience. The drug is still noted in official documents for its continued use, particularly for conditions like tinea capitis (scalp ringworm) in children, where it is recognized as a treatment option.

How should Grisovin be stored and disposed of?

Storage Requirements

Grisovin (Griseofulvin) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be kept in the original container and maintained tightly closed to preserve product integrity.

Storage Constraint Requirement
Temperature Do not freeze the product and avoid excess heat.
Protection Keep away from light and moisture to ensure stability.
Child Safety Store the medicine out of the reach of children, utilizing safety caps and secure placement.

Disposal Instructions

Regulatory guidance states that Grisovin should not be flushed down the toilet or disposed of in household wastewater. The preferred method for discarding unused or expired product is through an authorized medicine take-back program or by following specific government guidelines for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Grisovin found in:

A-Z Index: